Enabling High-Throughput Screening and Characterization of Targeted Protein Degraders with HiBiT Technology

Targeted protein degradation is emerging as a promising new modality in drug discovery. Degraders are highly attractive as therapeutics and offer unique advantages in achieving high degradation potency through catalytic, event-driven pharmacology without posing strict requirements on the target binding site or affinity. However, significant challenges persist to efficiently screen for degraders and characterize their cellular mechanisms and dynamic degradation responses. Join our featured speakers from Promega and Evotec to learn how high-throughput targeted protein degradation platforms can be developed using HiBiT technology and the assessment of cellular protein-protein or protein-small molecule interactions by NanoBRET® technology, including binary engagement, ternary complex formation, and ubiquitination.